Pharnext presenteert nieuwe synergetische resultaten van PCT864 op AD/PDTM 2017, de 13e internationale conferentie voor Alzheimer, Parkinson en aanverwante neurologische aandoeningen
PARIJS–(BUSINESS WIRE)– Pharnext SA (Paris:ALPHA) (FR00111911287 – ALPHA), een Frans biofarmaceutisch bedrijf dat een geavanceerd portfolio van medicijnen tegen neurodegeneratieve ziekten ontwikkelt, heeft vandaag aangekondigd positieve preklinische gegevens over zijn PLEODRUG™ PXT864 te presenteren op het congres AD/PD TM 2017, dat van 29 maart tot 2 april plaatsvindt in Wenen. PXT864 is in ontwikkeling als medicijn tegen Alzheimer.
Inmiddels is gebleken dat de effecten van goedgekeurde standaardmethoden voor de behandeling van Alzheimer, namelijk donepezil en memantine, van kortstondige duur zijn en bijwerkingen veroorzaken. Een verbeterde werking van deze medicijnen zou daarom een grote mijlpaal zijn voor Alzheimerpatiënten.
Pharnext combineerde in preklinische Alzheimermodellen de standaardbehandeling met zijn PLEODRUG™ PXT864 – een nieuwe kleine dosis van baclofen en acamprosaat. Data laten zien dat deze drievoudige combinatie (PXT864 + donepezil of memantine) groter effect heeft dan één van de medicijnen alleen.
Pharnext to Present New PXT864 Synergy Data at AD/PDTM 2017, the 13th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders |
||||||||||||||||||
|
PARIS–(BUSINESS WIRE)– Regulatory News: Pharnext SA (Paris:ALPHA) (FR00111911287 – ALPHA), a French biopharmaceutical company developing an advanced portfolio of products for neurodegenerative diseases, today announced that positive preclinical data for its PLEODRUG™ PXT864, in development for Alzheimer’s disease (AD), will be presented at the AD/PD TM 2017 congress on March 29 – April 2 in Vienna, Austria. Today, the use of approved standards of care (SOCs) in AD, i.e. donepezil and memantine, shows transient efficacy and is moreover associated with side effects. Thus, improving these drugs’ features would be a major milestone for patients with AD. In preclinical AD models, Pharnext combined these SOCs molecules with its PLEODRUG™ PXT864, a novel fixed low dose combination of baclofen and acamprosate. Data show that the efficacy of the tri-therapy combination (PXT864 + donepezil or memantine) was greater than the individual drugs alone. This is defined as a synergistic effect. Details of the data presentation are as follows:
The full abstract can be found here: PXT864 alone had already shown promising efficacy in AD during an exploratory Phase 2 trial. Data were presented in December 2016 at the Ninth Clinical Trials on Alzheimer’s Disease (CTAD) Conference in San Diego, CA. These preliminary preclinical and clinical findings will be used to design the next phase 2b clinical study to further evaluate the potential of PXT864 as the next generation AD therapy. PXT864 acts through a new mechanism of action and targets metabolic imbalance in the brains of patients suffering from neurodegenerative diseases. PXT864’s most advanced indication is Alzheimer’s disease. Development in other neurodegenerative diseases, including Parkinson’s disease and amyotrophic lateral sclerosis (ALS), is also planned. About Alzheimer’s Disease Alzheimer’s disease is an irreversible and progressive neurodegenerative dementia. It is characterized by neuronal death in brain structures implicated with memory leading to cognitive deficits such as thinking, memory, personality and behavior disorders. The disease typically develops and worsens gradually over the course of several years and ultimately leads to death. It affects around 44 million people worldwide. Unfortunately, three out of four patients are diagnosed once the disease is at a severe stage. Alzheimer’s disease has no cure and current existing therapies provide only short-lasting and modest symptomatic relief. About Pharnext Pharnext is an advanced clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics: Pharnext focuses on neurodegenerative diseases and has two lead products in clinical development: PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The company identifies and develops synergic combinations of repositioned drugs at low dose. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team. The company Pharnext is listed on Euronext Alternext Stock Exchange in Paris (ISIN code: FR00111911287). For more information, visit www.pharnext.com View source version on businesswire.com: http://www.businesswire.com/news/home/20170328006439/en/ Contacts Pharnext |
||||||||||||||||||